NexgenRx Management
Management criteria checks 3/4
NexgenRx's CEO is Ron Loucks, appointed in Mar 2003, has a tenure of 21.75 years. total yearly compensation is CA$313.34K, comprised of 75% salary and 25% bonuses, including company stock and options. directly owns 10.48% of the company’s shares, worth CA$1.86M. The average tenure of the management team and the board of directors is 5.5 years and 12.5 years respectively.
Key information
Ron Loucks
Chief executive officer
CA$313.3k
Total compensation
| CEO salary percentage | 75.0% |
| CEO tenure | 21.8yrs |
| CEO ownership | 10.5% |
| Management average tenure | 5.5yrs |
| Board average tenure | 12.5yrs |
Recent management updates
Recent updates
Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking
May 21
We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 10NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues
Mar 14Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today
Mar 07Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?
Oct 18Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?
Nov 30What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You
Aug 24Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up
Jun 03NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 19
How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CA$255k |
| Jun 30 2024 | n/a | n/a | -CA$25k |
| Mar 31 2024 | n/a | n/a | -CA$66k |
| Dec 31 2023 | CA$313k | CA$235k | -CA$332k |
| Sep 30 2023 | n/a | n/a | -CA$310k |
| Jun 30 2023 | n/a | n/a | -CA$244k |
| Mar 31 2023 | n/a | n/a | -CA$172k |
| Dec 31 2022 | CA$287k | CA$235k | -CA$22k |
| Sep 30 2022 | n/a | n/a | CA$3m |
| Jun 30 2022 | n/a | n/a | CA$4m |
| Mar 31 2022 | n/a | n/a | CA$4m |
| Dec 31 2021 | CA$230k | CA$215k | CA$4m |
| Sep 30 2021 | n/a | n/a | CA$2m |
| Jun 30 2021 | n/a | n/a | CA$2m |
| Mar 31 2021 | n/a | n/a | CA$2m |
| Dec 31 2020 | CA$153k | CA$140k | CA$2m |
| Sep 30 2020 | n/a | n/a | CA$1m |
| Jun 30 2020 | n/a | n/a | CA$483k |
| Mar 31 2020 | n/a | n/a | -CA$31k |
| Dec 31 2019 | CA$181k | CA$165k | -CA$208k |
| Sep 30 2019 | n/a | n/a | CA$38k |
| Jun 30 2019 | n/a | n/a | -CA$147k |
| Mar 31 2019 | n/a | n/a | -CA$438k |
| Dec 31 2018 | CA$181k | CA$165k | -CA$697k |
| Sep 30 2018 | n/a | n/a | -CA$1m |
| Jun 30 2018 | n/a | n/a | -CA$1m |
| Mar 31 2018 | n/a | n/a | -CA$793k |
| Dec 31 2017 | CA$181k | CA$165k | -CA$626k |
Compensation vs Market: Ron's total compensation ($USD218.05K) is above average for companies of similar size in the Canadian market ($USD164.16K).
Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.
CEO
Ron Loucks (74 yo)
21.8yrs
Tenure
CA$313,342
Compensation
Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.8yrs | CA$313.34k | 10.48% CA$ 1.9m | |
| Chief Financial Officer | 7.6yrs | CA$60.00k | 0.63% CA$ 112.2k | |
| Vice President of Operations | less than a year | CA$169.40k | no data | |
| Vice President of Administration | no data | no data | no data | |
| Lead Human Resources | no data | no data | no data | |
| Company Secretary | 3.5yrs | no data | no data | |
| Financial Controller | no data | no data | no data |
5.5yrs
Average Tenure
Experienced Management: NXG's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.8yrs | CA$313.34k | 10.48% CA$ 1.9m | |
| Independent Chairman | 18.8yrs | CA$30.00k | 0.88% CA$ 156.3k | |
| Director | less than a year | no data | no data | |
| Independent Director | 6.3yrs | CA$20.00k | 0.14% CA$ 25.0k |
12.5yrs
Average Tenure
74yo
Average Age
Experienced Board: NXG's board of directors are seasoned and experienced ( 12.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 09:40 |
| End of Day Share Price | 2024/12/16 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NexgenRx Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|